# Sift Bio

> Sift Biosciences is a preclinical biotechnology company developing a next-generation peptide immunotherapy platform that combines AI, metagenomics, and high-throughput T-cell screening to discover peptides that amplify immune responses for cancer and autoimmune disease.

Sift Bio is a UC Berkeley spinout founded in 2024. Its platform identifies microbially derived peptides that activate memory T cells capable of recognizing and responding to both microbial and cancer targets. Initial focus areas are immunologically "cold" solid tumors (microsatellite-stable colorectal and ovarian cancers) and autoimmune diseases.

## Pages

- [Home](https://siftbio.com/): Company overview, mission, and scientific approach.
- [Team](https://siftbio.com/team): Founders, scientific team, and board of directors.
- [Press](https://siftbio.com/press): News, announcements, and press releases.
- [Contact](https://siftbio.com/contact): Get in touch about science, partnerships, or careers.

## Press Releases

- [Sift Biosciences to Present at the 2026 BIO International Convention in San Diego (May 24, 2026)](https://siftbio.com/press/sift-biosciences-at-bio-2026-international-convention): CEO Dr. Yue Clare Lou will present Sift Biosciences at Startup Stadium during the 2026 BIO International Convention, with partnership and investor meetings throughout the week.
- [Sift Biosciences CEO Clare Lou Named to the Class of 2026 Termeer Fellows (March 24, 2026)](https://siftbio.com/press/clare-lou-named-2026-termeer-fellow): Dr. Yue Clare Lou joins 17 first-time life sciences CEOs selected by the Termeer Institute for its 2026 Fellows program.
- [Sift Biosciences Announces $3.7M Pre-seed Financing (February 17, 2026)](https://siftbio.com/press/sift-biosciences-announces-3-7m-pre-seed-financing): Pre-Seed round co-led by Freeflow Ventures and Lifespan Vision Ventures, with participation from Valuence Ventures, Eisai Innovation, SBI US Gateway Fund and others.
- [Sift Biosciences CEO Clare Lou Selected for the 2025 ACS BrightEdge Entrepreneurs (BEE) Program (February 17, 2025)](https://siftbio.com/press/clare-lou-named-2025-acs-brightedge-bee-fellow): Dr. Yue Clare Lou selected for the 2025 cohort of the ACS BrightEdge Entrepreneurs (BEE) Program, a cancer-focused early-stage venture accelerator run by the American Cancer Society's innovation and impact investment arm.
- [Sift Biosciences Selected for Plug and Play's Second Seattle Accelerator Cohort (September 19, 2025)](https://siftbio.com/press/sift-biosciences-selected-plug-and-play-seattle-cohort-2): Sift Biosciences joins ten startups in Plug and Play's second Seattle-based accelerator cohort, a 12-week program offering mentorship, corporate introductions, and networking across biotech, health tech, enterprise software, and cybersecurity.
- [Sift Biosciences Selected to Present at the 3rd Annual MBC BioLabs Oncology Forum (September 22, 2025)](https://siftbio.com/press/sift-biosciences-selected-mbc-biolabs-oncology-forum-2025): Sift Biosciences was selected to present at the 3rd Annual MBC BioLabs Oncology Forum in San Francisco, a curated gathering of early-stage oncology companies, investors, and pharmaceutical partners.
- [Sift Biosciences CEO Clare Lou Named to Forbes 30 Under 30 in Healthcare (January 1, 2025)](https://siftbio.com/press/clare-lou-named-forbes-30-under-30-healthcare): Dr. Yue Clare Lou recognized by Forbes on its 30 Under 30 list in Healthcare for her work advancing next-generation peptide immunotherapy.
- [Sift Biosciences Named Winner of the 2024 Eisai Innovation & MBC BioLabs Golden Ticket Competition (November 5, 2024)](https://siftbio.com/press/sift-biosciences-wins-eisai-mbc-biolabs-golden-ticket): Sift Biosciences won the 2024 Eisai Innovation and MBC BioLabs Golden Ticket Competition, earning one year of free lab space at MBC BioLabs in San Francisco.
- [Sift Biosciences Founder Clare Lou Awarded $1M WIES Fellowship from UC Berkeley's Innovative Genomics Institute (September 10, 2024)](https://siftbio.com/press/clare-lou-awarded-1m-wies-fellowship): Dr. Yue Clare Lou received $1 million in non-dilutive seed funding through the HS Chau Women in Enterprising Science (WIES) Program at IGI to accelerate development of Sift's microbial peptide-based cancer immunotherapies.

## Contact

- Email: info@siftbio.com
- Address: 733 Industrial Rd, San Carlos, California, USA